{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-15",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "San Diego",
      "state": "CA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Devices",
      "event_id": "72471",
      "recalling_firm": "Ameditech Inc",
      "address_1": "9940 Mesa Rim Rd",
      "address_2": "N/A",
      "postal_code": "92121-2910",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Worldwide Distribution - US (nationwide) and Internationally to Australia.",
      "recall_number": "Z-0314-2016",
      "product_description": "Premier Clia Waived 12 panel Tilt Cup, Item No. C12APC    These Drugs of Abuse Tests are one-step immunoassays for the qualitative detection of multiple drugs and drug metabolites in human urine. The configurations of these Drugs of Abuse Tests consist of a combination of drug strips, including Benzodiazepine (BZO). They are used to obtain a visual, qualitative result and are intended for professional and point of care use.                                             ¿¿¿",
      "product_quantity": "384 units",
      "reason_for_recall": "Ameditech is recalling drug abuse tests because they have shown reduced reactivity.",
      "recall_initiation_date": "20151020",
      "center_classification_date": "20151118",
      "termination_date": "20161109",
      "report_date": "20151125",
      "code_info": "141748"
    }
  ]
}